X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare J.B.Chemicals with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

J.B.CHEMICALS vs IPCA LABS - Comparison Results

J.B.CHEMICALS    Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    J.B.CHEMICALS IPCA LABS J.B.CHEMICALS/
IPCA LABS
 
P/E (TTM) x 17.1 28.1 61.0% View Chart
P/BV x 2.3 3.3 69.7% View Chart
Dividend Yield % 0.2 0.1 118.6%  

Financials

 J.B.CHEMICALS   IPCA LABS
EQUITY SHARE DATA
    J.B.CHEMICALS
Mar-16
IPCA LABS
Mar-18
J.B.CHEMICALS/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs318695 45.7%   
Low Rs200400 49.9%   
Sales per share (Unadj.) Rs148.0260.2 56.9%  
Earnings per share (Unadj.) Rs19.119.0 100.6%  
Cash flow per share (Unadj.) Rs23.933.1 72.4%  
Dividends per share (Unadj.) Rs0.501.00 50.0%  
Dividend yield (eoy) %0.20.2 105.8%  
Book value per share (Unadj.) Rs128.9213.0 60.5%  
Shares outstanding (eoy) m84.82126.20 67.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.1 83.1%   
Avg P/E ratio x13.628.9 47.0%  
P/CF ratio (eoy) x10.816.6 65.2%  
Price / Book Value ratio x2.02.6 78.1%  
Dividend payout %2.65.3 49.7%   
Avg Mkt Cap Rs m21,95169,120 31.8%   
No. of employees `0002.713.3 20.6%   
Total wages/salary Rs m1,8417,359 25.0%   
Avg. sales/employee Rs Th4,590.92,477.4 185.3%   
Avg. wages/employee Rs Th673.4555.2 121.3%   
Avg. net profit/employee Rs Th592.1180.6 327.8%   
INCOME DATA
Net Sales Rs m12,55132,836 38.2%  
Other income Rs m542418 129.6%   
Total revenues Rs m13,09333,254 39.4%   
Gross profit Rs m2,0554,505 45.6%  
Depreciation Rs m4121,777 23.2%   
Interest Rs m96240 39.8%   
Profit before tax Rs m2,0882,905 71.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m469511 91.8%   
Profit after tax Rs m1,6192,394 67.6%  
Gross profit margin %16.413.7 119.3%  
Effective tax rate %22.517.6 127.7%   
Net profit margin %12.97.3 176.9%  
BALANCE SHEET DATA
Current assets Rs m7,77819,455 40.0%   
Current liabilities Rs m4,35810,076 43.3%   
Net working cap to sales %27.228.6 95.4%  
Current ratio x1.81.9 92.4%  
Inventory Days Days5598 55.8%  
Debtors Days Days8067 119.5%  
Net fixed assets Rs m5,71320,260 28.2%   
Share capital Rs m170252 67.2%   
"Free" reserves Rs m10,54726,633 39.6%   
Net worth Rs m10,93726,886 40.7%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m15,57441,173 37.8%  
Interest coverage x22.813.1 174.3%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.80.8 101.1%   
Return on assets %11.06.4 172.0%  
Return on equity %14.88.9 166.2%  
Return on capital %20.010.8 185.5%  
Exports to sales %48.747.6 102.3%   
Imports to sales %7.114.9 47.6%   
Exports (fob) Rs m6,11515,642 39.1%   
Imports (cif) Rs m8894,884 18.2%   
Fx inflow Rs m6,16915,642 39.4%   
Fx outflow Rs m1,2854,884 26.3%   
Net fx Rs m4,88410,759 45.4%   
CASH FLOW
From Operations Rs m1,3973,411 40.9%  
From Investments Rs m-320-1,354 23.7%  
From Financial Activity Rs m-1,196-1,304 91.7%  
Net Cashflow Rs m-102753 -13.6%  

Share Holding

Indian Promoters % 55.4 45.9 120.7%  
Foreign collaborators % 0.3 0.0 -  
Indian inst/Mut Fund % 3.4 11.4 29.7%  
FIIs % 3.9 25.3 15.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 37.0 17.4 212.6%  
Shareholders   30,437 36,892 82.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare J.B.CHEMICALS With:   NOVARTIS  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare J.B.CHEMICALS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

J.B.CHEMICALS SHARE PRICE


Sep 21, 2018 (Close)

TRACK J.B.CHEMICALS

  • Track your investment in J.B.CHEMICALS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

J.B.CHEMICALS 5-YR ANALYSIS

COMPARE J.B.CHEMICALS WITH

MARKET STATS